Biotech Values

[ghmm]

NKTR/BMY:

IMHO, the NKTR/BMY team is rushing their Ph3 trials before the necessary info is collected.

Perhaps I could see BMY (even then I don't agree) but why would you say NKTR is rushing? Since their on-going costs are capped isn't it more value creating for their shareholders to be more aggressive even at the risk of fewer/partial (subgroups in indications) approvals?

Also, I don't know if you saw my comments earlier but the implication was the P3's will be designed that would possibly allow for early approval in some subgroups if remarkable efficacy is seen. And there was also a possibility to file in some indications from Phase 2 (again should the data be overwhelming).